Skip to main content

Evofem Biosciences, Inc.

EVFM
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001618835

No open-market purchases or sales by Evofem Biosciences, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding Evofem Biosciences, Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021All holders in Q3 2021

13F holders of EVFM: Q3 2021 compared with Q4 2021
MeasureQ3 2021Q4 2021Change
Holders7263−9
Shares26.8M23.6M−3.22M (−12.0%)
Value$19.8M$8.84M−$10.9M (−55.3%)

New holders (9)

Institutions that held Evofem Biosciences, Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to EVFM in Q4 2021
InstitutionSharesValue% of portfolio
Renaissance Technologies LLC140,379$53.0K0.00%
Tower Research Capital LLC (TRC)36,606$14.0K0.00%
HRT Financial LP16,771$6.00K0.00%
Spire Wealth Management13,000$5.00K0.00%
National Bank of Canada5,991$2.00K0.00%
Wagner Wealth Management, LLC34$00.00%
O'Dell Group, LLC8$00.00%
Future Financial Wealth Managment LLC332$00.00%
Widmann Financial Services, Inc.2$00.00%

Sold out (18)

Institutions that held Evofem Biosciences, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.